Gout and Hyperuricaemia: The Evidence Behind the Pathway

A 46-year-old Kannada-speaking bank officer from Shivamogga limps into the outpatient clinic. His right big toe became hot, red and too painful for a bedsheet two nights ago. He is a vegetarian, his blood pressure is treated with a thiazide, and a health check two years ago printed his serum urate as 8.4 mg/dL. His family doctor told him then to stop dal, spinach and mushrooms. He has, and he still has gout. This is an illustrative case, not a real patient.

The Hyperuricaemia and Gout Pathway tells you what to do for him: how to confirm the flare, what dose of colchicine, whether to start allopurinol, at what dose, and what to tell him about food. It no longer tells you why. The trials, the cohort figures and the Indian data used to sit in its Evidence tab. They have moved here, so that the tool stays quick at the bedside. By the end of this article you will know where each instruction came from, and how firm the ground is under it.

1. The raised urate on a health check

Two years ago, before any joint swelled, should anyone have started a drug for his 8.4 mg/dL? No guideline calls that standard care. But they do not say the same thing either, as the full table shows. The tool now shows it in two halves on a phone; here it is in one piece.

“Six expert bodies, six answers. Which one is right?” These bodies read the same literature and differ on how much evidence a recommendation needs, diverging most where the evidence is thinnest. That is not a failure of the guidelines. It is an honest picture of how little we know about the patient who has never had a flare.

The reason usually given for treating is cardiovascular and renal protection, and this is the evidence for it. Read the column on the right from top to bottom. The observational signal shrinks as the methods get stricter, and the randomised trials find nothing.

A Mendelian randomisation study uses the genes a person is born with, which raise or lower urate for life, as a natural experiment. If urate itself caused heart disease, people born with high-urate genes should have more of it. They do not, once the analysis is cleaned up (White 2016; Efstathiadou 2019). ALL-HEART (Mackenzie 2022), CKD-FIX (Badve 2020) and PERL (Doria 2020) then tested the drug directly, and FREED (Kojima 2019), the one trial pointing the other way, had a comparator arm that received allopurinol whenever the urate rose. So the tool does not offer urate lowering to protect the heart or the kidney.

2. The flare, and the joint that is also septic

Our patient’s toe looks like gout. It still has to be tapped if it can be, and the fluid sent for Gram stain and culture as well as crystals. “If the crystals are there, isn’t that the answer?” Not always. In 1,116 patients with crystal-induced arthritis between 2015 and 2024, 45 of them, 4 per cent, had concomitant septic arthritis (Duangkum 2025). Monosodium urate crystals were present in 80 per cent of those cases, fever in 95.6 per cent, the median synovial white cell count was 61,478 per microlitre, and mortality was 15.6 per cent. Older series report coexistence between 1.5 and 5.2 per cent. A septic joint can hold crystals too, and in that series it killed about one patient in six.

3. Colchicine: why the low dose

Indian colchicine comes as 0.5 mg, and EULAR’s regimen is written in those units: 1 mg, then 0.5 mg an hour later. “Isn’t a bigger dose more likely to settle the joint?” The trial says no. The evidence for the low dose: a randomised comparison against placebo of 1.8 mg over an hour and 4.8 mg over six hours (Terkeltaub 2010). Response at 24 hours 37.8 and 32.7 per cent, diarrhoea 23.0 against 76.9 per cent. Each arm was tested against placebo and not against the other, so the two are comparable rather than proven equal. The high dose brought three times the diarrhoea for no better response.

4. Why the target is 6 mg/dL

The rationale is physical, not statistical. Monosodium urate crystallises out of solution above roughly 6.8 mg/dL at body temperature, so holding the urate below 6 mg/dL keeps the tissue pool undersaturated and existing deposits dissolve. Think of sugar in tea: below the point at which the tea is saturated, the sugar at the bottom of the cup slowly goes back into solution. Above it, more settles out. Where the comparison stops working: a joint is not a cup, and dissolving takes months, not minutes. The tool does not give a source for the 6.8 figure.

5. Allopurinol: the dose that reaches target

If our patient goes on to need allopurinol, he starts at 100 mg a day, or 50 mg in chronic kidney disease stage 3 or worse, because a high starting dose is a risk factor for hypersensitivity. The tool keeps those doses. What has moved is the evidence that the dose may then be pushed up past the old creatinine clearance ceiling.

• The escalation trial: 183 people with gout, 52 per cent with a creatinine clearance below 60 mL/min, randomised to continue a clearance-based dose or to escalate (Stamp 2017, Ann Rheum Dis). At 12 months, 69 per cent of the escalation group were below 6 mg/dL against 32 per cent of controls, mean final doses 413 and 288 mg daily. No cases of allopurinol hypersensitivity syndrome in either arm, though the trial was not powered to detect one.
• By renal function at 24 months, in a post hoc analysis of that trial: target reached by 64.3 per cent below a clearance of 30 mL/min, 76.4 per cent between 30 and 60, and 75.0 per cent above 60, differences not significant (Stamp 2017, Arthritis Res Ther). Of the 14 patients below a clearance of 30, only 2 needed more than 300 mg daily.

“Then why the caution at the start?” Because of what the reaction does when it comes. Across 901 published cases from 1950 to 2012: all-cause mortality 14 per cent (109 of 788), renal impairment 48 per cent (182 of 376), concomitant diuretics 45 per cent (114 of 252) (Ramasamy 2013). Each proportion carries its own denominator because the source papers reported different things. Note the diuretics: our patient takes a thiazide. The tool keeps the rule that matters: any rash on allopurinol stops the drug that day, for good.

6. HLA-B*58:01: how strong the link is

One of the strongest drug-genotype associations described: pooled odds ratios of 96.6 in matched-control and 79.3 in population-control studies. An odds ratio near 100 means that, among people who had the severe reaction, carriers of the allele are many times over-represented. The tool gives no source for these two pooled figures. What the tool keeps, and what matters for our patient, are the Indian frequencies: 5.54 per cent in Kannada speakers, and a proportion carrying the allele roughly twice the allele frequency, which puts several Indian populations at or above the threshold at which APLAR would test.

7. Febuxostat: two trials pointing opposite ways

The tool keeps where the regulators and the ACR now stand. Here are the two trials behind that position, in the table as the tool carried it (White 2018; Mackenzie 2020).

One more line moved from the pyrazinamide paragraph. A prospective series found the mean urate rising from 5.1 to 7.4 mg/dL by week 8, hyperuricaemia in 43 per cent and arthralgia in 21.7 per cent. The tool does not name that series. Its rule stays: no corrective treatment below 11 mg/dL, and no reason to stop pyrazinamide for a urate below that.

8. The dal question

Our patient gave up dal on advice. Was that right? Every figure below comes from the Health Professionals Follow-up Study, a cohort of American men followed for 12 years. Four separate analyses of it are quoted, drawing on 45,869 to 47,150 men and 730 to 757 confirmed incident cases. Each compares the highest against the lowest quintile of intake unless stated (Choi 2004, N Engl J Med; Choi 2004, Lancet; Choi 2008; Choi 2007). A relative risk of 1.41 means a 41 per cent higher risk; 0.56 means a 44 per cent lower one.

Look at the row for purine-rich vegetables: peas, beans, lentils, spinach. No significant association. Now look at the rows for soft drinks, fruit juice and fructose. That is where the risk is. The cohort was of American men, not Indian vegetarians, so hold it with that caution. But it is why the tool says keep the dal, add curd and buttermilk, and stop the soft drinks and the daily juice.

9. Tumour lysis: the Indian rasburicase dose

The licensed rasburicase dose costs roughly 36,000 rupees a day in India; a single fixed dose of 1.5 mg costs roughly 6,000. Does the small dose work? At Chennai, in a series of 186 patients, it prevented laboratory or clinical tumour lysis in 87 per cent of the prophylactic group (Philips 2018). At Bengaluru 60 per cent of 90 patients normalised on it alone, and a further 18 per cent on a second dose (Lakshmaiah 2019). Both are Indian series, not randomised trials. The tool prints both regimens side by side, and the G6PD contraindication above them.

10. Uric acid stones: the arithmetic

The arithmetic is worth carrying. Uric acid has a pKa of about 5.3 to 5.5, sources vary, so below pH 5.5 most urinary urate is undissociated uric acid, far less soluble than the salt. Of an 800 mg daily load, about 600 mg is undissociated at pH 5.0 and about 100 mg at pH 6.5. That is why a uric acid stone is a disease of acid urine, and why raising the pH, not lowering the urate, is the first treatment.

11. The Indian figures that do not agree

Community surveys put gout prevalence in India remarkably low, while biochemical surveys find hyperuricaemia everywhere.

• Household surveys in the Pune region found an age and sex adjusted gout prevalence of 0.06 per cent in an urban population of 8,145 adults and 0.13 per cent in a rural one, against a worldwide range of 0.26 to 1.4 per cent (Joshi 2009; Misra 2024).
• Hyperuricaemia was found in 24.66 per cent of 197,097 subjects screened at 592 Indian camp locations, and in 32.7 per cent of 300 adults in rural Belagavi (Patel 2020; Muthusamy 2024).

The explanation may be biology, under-diagnosis in Indian primary care, the difference between a questionnaire and a blood test, or selection into camp cohorts. It is left open because whichever is right changes what to do with a raised urate in an Indian clinic.

Back to the clinic

Our patient’s toe is tapped, and the fluid goes for crystals, Gram stain and culture. He gets colchicine 1 mg and then 0.5 mg an hour later, written in milligrams. Whether to start allopurinol after this first flare is a question on which the guidelines differ, and the tool shows each one’s row rather than choosing. If he starts, he starts at 100 mg, he is asked about a rash at every visit, and his doctor weighs HLA-B*58:01 testing, a decision the tool leaves with the clinician. He goes back to his dal, adds curd, and stops the soft drinks. Each of those steps is a line in the tool. Now you know what stands behind each line.

Try this

A 38-year-old woman in her second month of anti-tubercular treatment has a serum urate of 9.6 mg/dL and aching knees, with no swollen joint. Her physician wants to start allopurinol and stop pyrazinamide. What do you advise? Illustrative case.

Answer. Neither. Pyrazinamide raises urate by blocking its secretion in the kidney, so it is expected, and the threshold for any corrective treatment is 11 mg/dL. Even above that, allopurinol is not the fix, because the problem is not overproduction. Moderate non-gouty aches are treated for the symptom and settle. Only persistent arthralgia that genuinely looks gouty justifies stopping the drug.

Take-home points

• A raised urate with no flare is not a reason to start a drug, and urate lowering is not given to protect the heart or kidney.
• Tap the hot joint and send it for culture as well as crystals: crystals do not exclude sepsis.
• Use the low colchicine dose, written in milligrams: 1 mg, then 0.5 mg an hour later.
• Start allopurinol low, then raise the dose until the urate is below 6 mg/dL. Stop it for good at the first rash.
• Let the vegetarian patient keep his dal. Stop the soft drinks and the daily fruit juice.

Declaration: the author built and maintains the tool. It is free to use. The figures in this article are those the tool carried in its Evidence tab on 4 November 2026, each from the source named beside it; where the tool names no source, the article says so.

References

1. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760.
2. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.
3. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38.
4. Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557-2568.
5. Janssens HJEM, Fransen J, van de Lisdonk EH, van Riel PLCM, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120-1126.
6. Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58-68.
7. Lorenzo JPP, Sollano MHMZ, Salido EO, et al. 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. Int J Rheum Dis. 2022;25(1):7-20.
8. Japanese Society of Gout and Uric & Nucleic Acids. Guideline for the management of hyperuricaemia and gout, 3rd edition, with the 2022 supplement. Thresholds and graded clinical questions read from the official summary in the Minds Guideline Library of the Japan Council for Quality Health Care. [The primary Japanese document itself could not be obtained]
9. Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases. Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases. Chin Med J (Engl). 2017;130(20):2473-2488.
10. Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-1528.
11. Stamp LK, Chapman PT, Barclay M, et al. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. Arthritis Res Ther. 2017;19(1):283.
12. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare. Arthritis Rheum. 2010;62(4):1060-1068.
13. Ramasamy SN, Korb-Wells CS, Kannangara DRW, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36(10):953-980.
14. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-1210.
15. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745-1757.
16. Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195-1205.
17. Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504-2513.
18. Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493-2503.
19. Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019;40(22):1778-1786.
20. White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-336.
21. Efstathiadou A, Gill D, McGrane F, Quinn T, Dawson J. Genetically determined uric acid and the risk of cardiovascular and neurovascular diseases: a Mendelian randomization study of outcomes investigated in randomized trials. J Am Heart Assoc. 2019;8(17):e012738.
22. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-1103.
23. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277-1281.
24. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-312.
25. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 2007;56(6):2049-2055.
26. Solloch UV, Schefzyk D, Schäfer G, et al. HLA allele and haplotype frequencies of eight Indian populations based on 130,518 registered stem cell donors. Front Immunol. 2025;16:1528177.
27. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11.
28. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854.
29. Philips A, Radhakrishnan V, Ganesan P, et al. Efficacy of single dose rasburicase (1.5 mg) for prophylaxis and management of laboratory tumor lysis syndrome. Indian J Hematol Blood Transfus. 2018;34(4):618-622.
30. Lakshmaiah KC, Babu KG, Rajeev LK, et al. Efficacy of a reduced-dose rasburicase: single-institution experience in India. Indian J Med Paediatr Oncol. 2019;40(3):406-408.
31. Mukherjee MB, Colah RB, Martin S, Ghosh K. Glucose-6-phosphate dehydrogenase (G6PD) deficiency among tribal populations of India: country scenario. Indian J Med Res. 2015;141(5):516-520.
32. Duangkum K, Saengmongkonpipat P, Tantiwong P, Siriphannon Y, Phungtaharn T. Prevalence and characteristics of concomitant septic and crystal-induced arthritis: a hospital database and literature review. Rheumatol Immunol Res. 2025;6(3):179-187.
33. Misra DP, Sharma A, Dharmanand BG, Chandrashekara S. The epidemiology of rheumatic diseases in India. Indian J Rheumatol. 2024;19(1):54-61.
34. Joshi VL, Chopra A. Is there an urban-rural divide? Population surveys of rheumatic musculoskeletal disorders in the Pune region of India using the COPCORD Bhigwan model. J Rheumatol. 2009;36(3):614-622.
35. Patel H, Shah D. Hyperuricemia prevalence in Indian subjects with underlying comorbidities of hypertension and/or type 2 diabetes: a retrospective study from subjects attending hyperuricemia screening camps. Int J Res Med Sci. 2020;8(3):794-800.
36. Muthusamy S, Kulkarni RR, Khot PB. Prevalence of hyperuricemia and its risk factors among residents of a rural field practice area in Belagavi, India. Natl J Community Med. 2024;15(1):29-35.
37. World Health Organization. Product information for pyrazinamide 500 mg tablets. WHO Prequalification of Medicines Programme, WHOPAR part 4.